Literature DB >> 10356707

Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys.

D K Monteith1, M J Horner, N A Gillett, M Butler, R Geary, T Burckin, T Ushiro-Watanabe, A A Levin.   

Abstract

Antisense phosphorothioate oligodeoxynucleotides are therapeutic agents that provide target specificity resulting from Watson-Crick base pairing. However, there are nonspecific effects that in some instances result in toxicity. These compounds accumulate in the kidney and induce renal proximal tubular degeneration at high doses. The relationship between accumulation of phosphorothioate oligodeoxynucleotides in the kidney, indicators of renal toxicity, and histomorphology were investigated in rhesus monkeys. Monkeys received vehicle or an escalating dose regimen of 3, 10, 40, and 80 mg/kg of ISIS 2105 and were then evaluated for changes in clinical pathology indices, urinalysis parameters, and renal histopathology. Urinalysis revealed an increase in protein levels and a slight increase in blood content following the third 40 mg/kg dose and continuing through the 80 mg/kg doses, whereas other urinary markers of renal toxicity were unchanged. Creatinine clearance was slightly decreased in monkeys during the 80 mg/kg dose cycle. Granulation in the cytoplasm of proximal tubular epithelial cells was evident by microscopic examination of kidney and was present at all doses examined and increased with dose. Immunohistochemical staining localized the oligodeoxynucleotide within these granules. Histopathologic changes consisting of minimal to moderate tubular degeneration were present only at the higher doses of 40 and 80 mg/kg and at high tissue concentrations, and these changes occurred concurrent with functional alterations, whereas lower doses (< or = 10 mg/kg) did not affect a pathologic or functional change.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356707     DOI: 10.1177/019262339902700306

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  11 in total

1.  Elucidation of the Mechanism of Increased Activity of Immunostimulatory DNA by the Formation of Polypod-like Structure.

Authors:  Kohta Mohri; Kengo Nagata; Shozo Ohtsuki; Shiori Toyama; Mao Nonomura; Yuki Takahashi; Yoshinobu Takakura; Makiya Nishikawa; Shinji Sakuma
Journal:  Pharm Res       Date:  2017-08-08       Impact factor: 4.200

Review 2.  Gene therapy for renal disorders: what are the benefits for the elderly?

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Renal gene transfer: nonviral approaches.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Mol Biotechnol       Date:  2003-07       Impact factor: 2.860

4.  Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.

Authors:  Prabuddha Mukherjee; Edita Aksamitiene; Aneesh Alex; Jindou Shi; Kajari Bera; Chi Zhang; Darold R Spillman; Marina Marjanovic; Michael Fazio; Punit P Seth; Kendall Frazier; Steve R Hood; Stephen A Boppart
Journal:  Nucleic Acid Ther       Date:  2021-11-19       Impact factor: 4.244

5.  From the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides.

Authors:  Annamaria Braendli-Baiocco; Matthias Festag; Kamille Dumong Erichsen; Robert Persson; Michael J Mihatsch; Niels Fisker; Juergen Funk; Susanne Mohr; Rainer Constien; Corinne Ploix; Kevin Brady; Marco Berrera; Bernd Altmann; Barbara Lenz; Mudher Albassam; Georg Schmitt; Thomas Weiser; Franz Schuler; Thomas Singer; Yann Tessier
Journal:  Toxicol Sci       Date:  2017-05-01       Impact factor: 4.849

6.  GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells.

Authors:  Sabine Sewing; Marcel Gubler; Régine Gérard; Blandine Avignon; Yasmin Mueller; Annamaria Braendli-Baiocco; Marielle Odin; Annie Moisan
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20

7.  Therapy with 2'-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption.

Authors:  Manoe J Janssen; Tom T G Nieskens; Tessa A M Steevels; Pedro Caetano-Pinto; Dirk den Braanker; Melissa Mulder; Yolanda Ponstein; Shaun Jones; Rosalinde Masereeuw; Cathaline den Besten; Martijn J Wilmer
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-06       Impact factor: 8.886

8.  Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice.

Authors:  Elena Bassi; Sofia Falzarano; Marina Fabris; Francesca Gualandi; Luciano Merlini; Gaetano Vattemi; Daniela Perrone; Elena Marchesi; Patrizia Sabatelli; Katia Sparnacci; Michele Laus; Paolo Bonaldo; Paola Rimessi; Paola Braghetta; Alessandra Ferlini
Journal:  J Biomed Biotechnol       Date:  2012-10-02

9.  Blocking TLR7- and TLR9-mediated IFN-α production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection.

Authors:  Muhamuda Kader; Amanda P Smith; Cristiana Guiducci; Elizabeth R Wonderlich; Daniel Normolle; Simon C Watkins; Franck J Barrat; Simon M Barratt-Boyes
Journal:  PLoS Pathog       Date:  2013-07-25       Impact factor: 6.823

Review 10.  Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies.

Authors:  Marina A Dobrovolskaia
Journal:  Molecules       Date:  2019-12-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.